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The complex relationship between both theTh1/Th17 and Tc1/Tc17 axis and innate defences in the intestinal mucosa during HIV-1
infection has not beenwell characterized.This study examined the frequency, phenotype, and functional status of T cell populations
in the gut-associated lymphoid tissue and peripheral blood of virologically suppressed HIV-1-infected patients on therapy, focusing
on the Th1, Th17, Tc1, and Tc17 cell subsets. We found a persistent immune cell activation (CD38 and HLADR expression) into
the GALT despite the higher levels of Th17 and Tc17 in respect to peripheral blood. An upregulation of type I IFN response in
GALT compared to the peripheral blood compartment was also recorded. Furthermore, IFN-𝛼/𝛽 levels were negatively related to
the frequencies of Th1 na¨ıve cells and Tc1 cell subsets (na¨ıve, central memory, and effector memory) in the GALT. In contrast, no
relationships between type I IFN response andTh1 or Tc1 cell subsets in peripheral blood compartment and between IFN-𝛼/𝛽 and
Th17/Tc17 in both GALT and peripheral blood district were recorded. These data indicate that prolonged antiretroviral treatment
improves GALT immune function despite the persistence of immune activation and type I IFN response in chronic HIV-1 positive
patients.
1. Introduction
IL-17-producing CD4+ T cells (Th17) are known to regulate
the permeability of gut mucosa and microbial translocation.
T helper type 17 cells mediate a variety of inflammatory
reactions through their selective secretion of IL-17A, IL-17F,
and IL-22.
Recent studies have demonstrated that Th17 cells are
depleted during HIV/SIV infections, suggesting that cell
depletion may accelerate the progression to AIDS [1, 2].
The early initiation of antiretroviral therapy (ART) has been
reported to preserve the number and function of Th17 with
consequent control of HIV-related immune activation [1–
3]. Accordingly, HIV-1-infected individuals receiving ART
undergo effective CD4+ T cell restoration and this is asso-
ciated with enhanced CD4+ Th17 cell accumulation with-
out complete restoration [4]. Furthermore, although IL-17-
secreting CD4+ and CD8+ T cells have been reported, very
little is known about the CD8+ T subset in HIV-1 infection
and its relationship with immune response activation.
A variety of signals can block Th17 commitment includ-
ing IFN-𝛾, IL-4, and IL-12 [5]. Furthermore, Harrington
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et al. showed that the CD4+ T cell effector cytokine IFN-𝛾
potently suppressed the development of the IL-17-producing
effector T cells from na¨ıve CD4+ precursor cells, providing a
mechanism by which the T helper type 1 (Th1) developmental
program “antagonizes” the Th17 developmental program
and contributes to lineage divergence. Interestingly, IFN-𝛼/𝛽
was also demonstrated to have a negative impact on Th17
development in mice [6], recently extended to human Th17
cells [7]. Therefore, the dysregulated Th17 response during
HIV-1 infection could in part be explained by the reported
ability of type I IFN to suppress Th17 development [8, 9]. In
this regard, the mucosal antiviral responses appeared to be
largely type I IFN-driven and included factors that inhibit
HIV-1 budding (tetherin/BST2) and infectivity (APOBEC3G)
[10]. However, no studies on the relationships between Th17
and type I IFN response have been performed so far. Besides
thewell-established detrimental effects of type IFN in chronic
HIV-1-infected patients, this complex family of cytokines also
seems to regulate the effector and memory T cell functions
[5, 11, 12].
To our knowledge, this is the first study to evaluate the
relationship between type I IFN activation and IFN-𝛾 or IL-
17A expressing CD3+CD4+ or CD3+CD8+ T cell subsets in
the gut-associated lymphoid tissue (GALT) of HIV-1-infected
subjects.The objectives of the study were to compare the gene
expression of IFN-𝛼, IFN-𝛽, and IFN receptor (R1) between
peripheral blood cells and GALT collected from HIV-1-
infected patients who achieved a virological suppression
in response to ART therapy. In addition, the relationships
between activation of type I IFN response and IFN-𝛾 or IL-
17A-producing CD4+ or CD8+ (Tc17) T cell subsets (na¨ıve,
central memory, and effector memory) were evaluated.
2. Methods
2.1. Patients. From May to July 2014, ten HIV-1 positive
patients successfully treated with ART were recruited at the
Division of Infectious Diseases, Department of Public Health
and Infectious Diseases, Hospital of “Sapienza” University of
Rome (Italy).
The study was approved by the institutional review
board (Department of Public Health and Infectious Diseases,
“Sapienza” University of Rome and the Ethics Committee of
Umberto I General Hospital, Rome). All study participants
gave written informed consent.
2.2. Laboratory Procedures, Data Collection, and Analy-
sis Sampling. Patients were sampled for peripheral blood
(20mL) and underwent endoscopic procedures. Colonic
washing was carried out by PEG administration 24 hours
before the examination. The endoscopic procedure was per-
formed with conscious sedation (midazolam 5mg/iv) using
large cup forceps (Radial Jaw 4, Boston Scientific, Natick,
Massachusetts, USA). All HIV-1 positive patients underwent
a total colonoscopy and retrograde ileoscopy for at least 10 cm
of distal ileum with conventional or slim scope (model CF
or PCF-160 AI, Olympus Medical Europe GmbH, Hamburg,
Germany). We obtained specimens (2 biopsies from each
site) from the terminal ileum, cecum, ascending, transverse,
and descending colon. T cell phenotype and activation
markers were analyzed on freshly isolated peripheral blood
mononuclear cells (PBMCs) and lamina propria lymphocytes
(LPLs) and T cell phenotype and cytokine expression were
evaluated after overnight cell culture. One aliquot each of
PBMCs and LPLs was stored as dried pellets for RNA
extraction.
2.3. Specimen Processing. Peripheral blood samples were
collected in tubes containing ethylenediaminetetraacetic acid
and plasma were previously separated by centrifugation.
Bloodwas processed to obtain PBMCs by Ficoll gradient cen-
trifugation (Lympholyte, Cedarlane Labs, Hornby, Ontario,
Canada). Gut biopsies from each intestine site were pooled
and processed. Briefly, biopsies collected in RPMI 1640 were
washed twice with EDTA wash media, resuspended, and
incubated for 1 hour at room temperature in EDTA solution
5mM. Supernatant containing intraepithelial lymphocytes
was removed, and biopsies were digested by 1 hour incubation
at 37∘C with 1mg/mL collagenase (Sigma-Aldrich, Milan,
Italy) and 1.5U DNAse I (Sigma-Aldrich, Milan, Italy),
allowing the isolation of LPLs that were filtered through a
70 𝜇m cell strainer.
2.4. Cell Cultures. PBMCs and LPLs were seeded at concen-
trations of 2×106 cells/mL and 1.5× 106 cells/mL, respectively,
with RPMI media +20% heat inactivated fetal bovine serum
(FBS) and cultured overnight at 37∘C and 5% CO
2
in
the presence of medium alone or phorbol myristyl acetate
(PMA) (3 ng/mL, Sigma Aldrich, Milan Italy) and ionomycin
(1 𝜇g/mL, SigmaAldrich,Milan, Italy). BDGolgiStop (Becton
Dickinson, San Jose, CA, USA) was added to all culture
conditions. Cells were collected, washed, and stained for T
cell phenotype and cytokine expression.
2.5. Monoclonal Antibody and T Cell Phenotyping. Pheno-
type and activation were evaluated by multiparameter flow
cytofluorimetric analysis on freshly isolated PBMCs and
LPLs by the following anti-human monoclonal antibodies:
CD3-PerCP, CD4+-APC-Vio770, CD8+-FITC, CD45RO-PE-
Vio770, CD27-VioBlue, CD38-APC, and HLA-DR-PE (Mil-
tenyi Biotec, Bergisch Gladbach, Germany).
Cultured cells were fixed, permeabilized (BD Cytofix/
Cytoperm, Becton Dickinson, San Jose, CA, USA), and
stained with combinations of fluorochrome-labeled mon-
oclonal antibodies: CD3-PerCP, CD4-APC-Vio770, CD8-
FITC, CD45RO-PE-Vio770, CD27-VioBlue, IFN-𝛾-APC, and
IL-17A-PE (Miltenyi Biotec, Bergisch Gladbach, Germany).
CD3+CD4+ cells expressing IFN-𝛾 or IL-17A were identified
as Th1 and Th17, respectively; CD3+CD8+ cells expressing
IFN-𝛾 or IL-17A were identified as Tc1 and Tc17, respectively;
CD3+CD4+ andCD3+CD8+ expressing both IFN-𝛾 and IL-17
were defined as CD4+ DP and CD8+ DP T cells, respectively.
T cell subpopulations were identified according to the
following phenotypic combinations: CD27+CD45RO-
(naı¨ve), CD27+CD45RO+ (central memory), and
CD27−CD45RO+CD4+ (effector memory) cells [13].
Acquisitions were performed on Miltenyi Biotec flow
cytometer-MACSQuant Analyzer (8 fluorescence channels, 3
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Figure 1: Activation markers, IFN-𝛾 and IL-17A expression in CD4+ and CD8+ T cells subsets in blood and in gut. Panel (a): representative
flow cytometry plots outlining CD38 and HLA-DR expression on naı¨ve, effector, and central memory CD4+ and CD8+ lymphocytes derived
from peripheral blood mononuclear cells (PBMCs) and gut-associated lymphoid tissue (GALT). Panel (b): representative flow cytometry
plots outlining IFN-𝛾 and IL-17A intracitoplasmatic expression on na¨ıve, effector, and central memory CD4+ (Th1 andTh17) and CD8+ (Tc1
and Tc17) lymphocytes derived from PBMCs and GALT.
lasers) and datawere analyzed usingMACSQuantify software
2.5 (Miltenyi Biotec, Bergisch Gladbach, Germany) with the
same gating strategy applied to all samples.
At least 100,000 and 10,000 events in the CD3+ lympho-
cyte gate were analyzed for PBMCs and LPLs, respectively.
Representative flow cytometry plots outlining activation
markers, IFN-𝛾 and IL-17A expression in CD4+ and CD8+
T cells subsets in blood (PBMCs) and in gut (GALT), are
reported in Figure 1.
2.6. Virological Analysis. Plasma samples were analyzed for
HIV-1 RNA copy number by VERSANT HIV-1 RNA 1.0
kPCR assay (Siemens) with a detection limit of 37 copies/
mL.
2.7. TaqMan-Based Real-Time RT-PCR Assays for mRNA
Expression. Quantitative real-time PCR for IFN-𝛼, IFN-
𝛽, and IFNR1 was carried out with the LightCycler 480
instrument (Roche, Basel, Switzerland). Briefly, total RNA
was extracted from PBMCs and LPLs using the RNeasy
Plus Universal Tissue Mini Kit (Invitrogen, Carlsbad, CA,
USA) and reverse transcribed using theHigh-Capacity cDNA
Reverse Transcription Kit (Applied Biosystem), according to
the manufacturer’s protocol. Primers and probes for each
gene were added to the Probes Master Mix (Roche, Basel,
Switzerland) at 500 and 250 nM, respectively, in a final vol-
ume of 20𝜇L. The housekeeping gene 𝛽-glucuronidase [14]
was used as an internal control. Gene expression values were
calculated by the comparative Ct method. The primers and
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Table 1: Th17 and Th1 frequencies in peripheral blood and gut-associated lymphoid tissue (GALT) samples collected from HIV-1-infected
patients (𝑛 = 10) who achieved virological suppression in response to ART therapy.
Frequencies GALT Peripheral blood 𝑝 values
Th17 cells (median/range) 1.06/0.21–3.66 0.26/0.00–0.67 𝑝 = 0.007
Th1 cells (median/range) 5.71/0.23–25.19 0.16/0.01–28.72 𝑝 = 0.059
CD4+ DP T cells (median/range) 0.17/0.0–2.28 0.005/0.0–0.12 p = 0.017
Na¨ıve Th17 cells (median/range) 1.19/0.0–8.73 0.09/0.0–0.36 p = 0.008
Na¨ıve Th1 cells (median/range) 1.01/0.23–11.56 0.04/0.0–13.0 𝑝 = 0.79
Na¨ıve CD4+ DP T cells (median/range) 0.0/0.0–0.49 0.0/0.0–0.05 𝑝 = 0.69
Central memoryTh17 cells (median/range) 0.935/0.0–3.87 0.24/0.00–1.19 p = 0.013
Central memoryTh1 cells (median/range) 7.65/0.19–33.14 0.22/0.0–36.21 𝑝 = 0.169
Central memory CD4+ DP T cells (median/range) 0.15/0.0–3.15 0.01/0.0–0.14 p = 0.011
Effector memoryTh17 cells (median/range) 0.48/0.0–4.05 0.21/0.00–1.61 p = 0.037
Effector memoryTh1 cells (median/range) 3.28/0.00–19.53 0.33/0.0–47.04 𝑝 = 0.959
Effector memory CD4+ DP T cells (median/range) 0.16/0.0–2.03 0.0/0.0–0.34 p = 0.028
∗Wilcoxon test for paired samples was used to compare Th17 andTh1 frequencies in peripheral blood and GALT. Significant values are highlighted in bold.
probe sequences used for IFN-𝛼 (Hs. PT.58.24294810.g), IFN-
𝛽 (Hs. PT.58.39481063.g), and IFNR1 (Hs. PT.58.25402720.g)
were purchased from Integrated DNA Technologies (IDT),
Iowa, USA.
2.8. Statistical Analysis. Statistical analyses and graphic pre-
sentationwere done using SPSS software, version 20.00 (IBM,
Somers, NY, USA) on data obtained from PBMC and gut
samples of 10HIV-1 positive patients. In particular, peripheral
and intestinal districts were compared by Wilcoxon test for
paired samples. Results are given as medians, ranges, and
percentages. Linear regression with Spearman’s correlation
coefficient was used to evaluate correlations between quan-
titative variables. Differences were considered statistically
significant when 𝑝 < 0.05.
3. Results
3.1. Participant Characteristics. All study participants were
Caucasian men with a median age of 42 years (22–53 years).
They initiated therapy during chronic infection and had been
on ART for a median of 6 years (IQR, 1.75 to 16.25 years);
pretherapy median CD4+ cell count was 255 cells/mm3
(IQR, 42.75 to 406.75 cells/mm3), and HIV-1 RNA copies
median value was 5.0 Log/mL (IQR, 4.81 to 5.61 Log/mL). All
subjects had been virologically suppressed (<37 HIV-1 RNA
copies/mL) for at least 1 year at the time of gut biopsy; their
median CD4+ cell count was 674 cells/mm3 (IQR, 564 to 824
cells/mm3).
3.2. Th17 and Th1 Frequencies in Peripheral Blood and GALT.
We compared the Th17 and Th1 frequencies in peripheral
blood and GALT samples collected from treated HIV-1-
infected patients who had shown a virological response to
ART therapy. As seen fromTable 1, themedian frequencies of
Th17, naı¨ve Th17, and CD4+ DP T cells were higher in GALT
than in peripheral blood (resp., 𝑝 = 0.007, 𝑝 = 0.017, and
𝑝 = 0.008). Furthermore, a trend toward a higher median
frequency of Th1 in GALT than in peripheral blood was
observed (𝑝 = 0.059, Table 1). Similar results were obtained
comparing the frequencies of central memory and effector
memory CD4+ T cell subpopulations in the peripheral and
GALT compartments. In particular, the median frequencies
of both central and effector memory Th17 cell subsets were
significantly higher in GALT than in peripheral blood (𝑝 =
0.013 and 𝑝 = 0.037, resp.). The individual values of Th17
frequencies for na¨ıve and memory subsets are plotted in
Figure 2. The same trend was observed for the central and
effector memoryTh1 cell subsets although the differences did
not reach statistical significance (Table 1). Lastly, we found
that the median frequencies of both central and effector
memory CD4+ DP T cells were statistically higher in GALT
than in peripheral blood (resp., 𝑝 = 0.011 and 𝑝 = 0.028,
Table 1).
3.3. Tc17 and Tc1 Frequencies in Peripheral Blood and GALT.
Having observed a higher frequency of Th17/Th1 cells in the
GALT of HIV-1-infected patients compared to that measured
in the peripheral blood, we analyzed the Tc17 and Tc1
frequencies in the same compartments. As seen from Table 1,
the median frequencies of Tc17, na¨ıve Tc1, and CD8+ DP T
cells were significantly higher in GALT than in peripheral
blood (resp., 𝑝 = 0.018, 𝑝 = 0.017 and 𝑝 = 0.005, Table 2).
A trend towards a higher median frequency of naı¨ve Tc17
cells in GALT than in peripheral blood was also found (𝑝 =
0.059, Table 2). In contrast, no statistical differences were
observed for the frequencies of Tc1, central memory Tc17,
central memory Tc1, or central memory CD8+ DP T subsets
betweenGALT and peripheral blood. Furthermore, we found
that the median frequencies of effector memory Tc17 cells
were significantly higher in GALT than in peripheral blood
(𝑝 = 0.035, Table 2) while the median frequencies of effector
memory Tc1 and CD8+ DP T cells were similar in the
two compartments analyzed. The individual values of Tc17
frequencies for na¨ıve and memory subsets are plotted in
Figure 2.
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Figure 2: Th17 and Tc17 frequencies in lymphocytes subsets derived from peripheral blood mononuclear cells (PBMC) and gut-associated
lymphoid tissue (GALT). Dot plots represent the frequencies ofTh17 andTh1 cells in na¨ıve (N), effector memory (E.M.), and central memory
(C.M.) CD4+ and CD8+ in PBMC and in GALT (Wilcoxon test for paired samples ∗, ∗∗, and ∗ ∗ ∗ = 𝑝 < 0.05).
Table 2: Frequencies of Tc17 and Tc1 in peripheral blood and gut-associated lymphoid tissue (GALT) samples collected from HIV-1-infected
patients (𝑛 = 10) who achieved virological suppression in response to ART therapy.
Frequencies GALT Peripheral blood 𝑝 values
Tc17 cells (median/range) 0.21/0.00–1.50 0.03/0.00–0.1 p = 0.018
Tc1 cells (median/range) 10.59/0.32–56.34 0.36/0.0–58.24 𝑝 = 0.114
CD8+ DP T cells (median/range) 0.095/0.0–1.16 0.005/0.0–0.11 p = 0.017
Na¨ıve Tc17 cells (median/range) 0.17/0.0–1.9 0.11/0.0–0.27 𝑝 = 0.059
Na¨ıve Tc1 cells (median/range) 6.24/0.37–41.74 0.49/0.0–31.61 p = 0.005
Na¨ıve CD8+ DP T cells (median/range) 0.0/0.0–0.41 0.01/0.0–0.07 𝑝 = 0.262
Central memory Tc17 cells (median/range) 0.16/0.0–1.47 0.05/0.00–0.51 𝑝 = 0.169
Central memory Tc1 cells (median/range) 15.38/0.52–58.75 1.36/0.0–72.9 𝑝 = 0.386
Central memory CD8+ DP T cells (median/range) 0.09/0.0–1.17 0.04/0.0–1.17 𝑝 = 0.063
Effector memory Tc17 cells (median/range) 0.14/0.0–1.64 0.025/0.00–0.09 p = 0.035
Effector memory Tc1 cells (median/range) 10.27/0.27 0.45/0.0–83.54 𝑝 = 0.720
Effector memory CD8+ DP T cells (median/range) 0.00/0.0–1.24 0.00/0.00–1.64 𝑝 = 0.721
∗Wilcoxon test was used to compare Tc17 and Tc1 frequencies in peripheral blood and GALT. Significant values are highlighted in bold.
3.4. CD4+ and CD8+ T Cell Activation in Peripheral Blood
and GALT. To estimate the activation of T cells in peripheral
blood and intestine, we analyzed the frequencies of CD4+ and
CD8+ T cells expressing HLA-DR, CD38 and coexpressing
CD38 and HLA-DR.The results are reported in Figure 3.The
median frequencies of CD4+ cells expressing HLA-DR and
coexpressing HLA-DR and CD38 were higher in GALT than
in peripheral blood (13.55 versus 4.38: 𝑝 = 0.005, and 4.85
versus 1.35: 𝑝 = 0.005 resp.); these differences seemed to be
driven by HLA-DR, as no statistically significant differences
were observed with CD38 alone (10.6 versus 14.9, 𝑝 =
0.203). Similar statistical differences in expression of HLA-
DR antigen between intestine and peripheral blood were also
observed in the central memory and na¨ıve subsets of CD4+
T cells (14.85 versus 1.87: 𝑝 = 0.005, and 12.15 versus 4.40:
𝑝 = 0.005 resp.). Furthermore, we found that the frequencies
of CD4+ T cells expressing CD38 antigen were significantly
higher in GALT than in peripheral blood within the effector
memory and central memory subpopulations (9.51 versus
3.26: 𝑝 = 0.017, and 15.24 versus 6.61: 𝑝 = 0.047, resp.). By
contrast, within the CD4+ T cells with na¨ıve phenotype, the
expression of CD38 antigen was higher in peripheral blood
than in intestine (24.05 versus 13.58: 𝑝 = 0.028). Moreover,
median frequencies of naı¨ve and central memory CD4+ T
cells coexpressing HLA-DR and CD38 were higher in GALT
than in peripheral blood (8.87 versus 0.88:𝑝 = 0.005, and 5.12
versus 1.24: 𝑝 = 0.005, resp.).
As far as the analysis of CD8+ T cells expressing HLA-
DR and CD38 and coexpressing CD38 and HLA-DR is
concerned, the frequencies of CD8+ T cells expressing CD38
antigen were higher in gut than in peripheral blood (9.50
versus 2.86: 𝑝 = 0.028); the central memory and effector
memory CD8+ T subpopulations also expressed more CD38
in intestine than in peripheral blood (7.64 versus 3.73: 𝑝 =
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Figure 3: CD38 and HLA-DR expression in lymphocytes subsets derived from peripheral blood mononuclear cells (PBMCs) and gut-
associated lymphoid tissue (GALT). Dot plots represent the frequencies of expression of CD38 (Panel (a)) HLA-DR (Panel (b)) and CD38 and
HLA-DR (Panel (c)) in naı¨ve (N), effector memory (E.M.), and central memory (C.M.) CD4+ and CD8+ in PBMC and in GALT (Wilcoxon
test for paired samples ∗, ∗∗, and ∗ ∗ ∗ = 𝑝 < 0.05).
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Figure 4: Comparison of the levels of interferon (IFN)-𝛼, IFN-
𝛽, and IFN receptor- (R1-) mRNA in the gut-associated lymphoid
tissue (GALT) and peripheral blood mononuclear cells (PBMCs)
collected from treated HIV-1-infected patients who had achieved
viral load suppression (<37 HIV-1 RNA copies/mL) in response to
ART therapy. IFN-𝛼 (GALT versus PBMCs) 𝑝 = 0.01; IFN-𝛽 (GALT
versus PBMCs) 𝑝 = 0.01; IFNR1 (GALT versus PBMCs) 𝑝 = 0.01.
Wilcoxon test was used to compare IFN-𝛼, IFN-𝛽 and IFNR1 in
GALT and PBMC.
0.013, and 15.04 versus 2.94: 𝑝 = 0.005, resp.). We also
observed that the frequencies of CD8+ T cells expressing
HLA-DR antigen were higher in GALT than in peripheral
blood (14.31 versus 8.41: 𝑝 = 0.013); the central memory and
na¨ıve CD8+ T subpopulations also expressed more CD38 in
GALT compared to that in peripheral blood (17.14 versus 7.19:
𝑝 = 0.013, and 16.36 versus 3.87: 𝑝 = 0.005, resp.). The na¨ıve
CD8+ T subpopulation coexpressingHLA-DR andCD38was
higher in GALT than in peripheral blood (1.6 versus 0.35:
𝑝 = 0.013) (Figure 3).
3.5. Relationship between Type I IFN Activation and the Fre-
quencies of Th1, Tc1, Th17, Tc17, CD4+, and CD8+ T Cells Acti-
vated in Peripheral Blood and GALT Compartments. Next,
we evaluated whether there was any relationship between
endogenous type I IFN production and the frequencies of
na¨ıve and memory Th1/Th17 and Tc1/Tc17 cells and those
of CD4+ and CD8+ T cells expressing HLA-DR, CD38 and
coexpressing CD38 and HLA-DR. First, we examined the
IFN-𝛼, IFN-𝛽, and IFNR1 gene expression in PBMCs and
GALT collected from HIV-1-infected patients who achieved
a virological suppression in response to ART. Results indi-
cated that transcript levels of IFN-𝛼, IFN-𝛽, and IFNR1 are
extremely variable in both PBMCs and GALT [coefficient
of variation (CV) > 100%]. However, we found that median
values of IFN-𝛼, IFN-𝛽, and IFNR1-mRNAs were, respec-
tively, 21-, 40-, and 16-fold higher in GALT compared to those
measured in PBMCs (Figure 4, IFN-𝛼: 𝑝 = 0.01; IFN-𝛽: 𝑝 =
0.01; IFNR1: 𝑝 = 0.01). A coordinated activation among
type I IFN members was observed in GALT as evidenced
by the strong correlations between IFN-𝛼 and IFN-𝛽 and
between IFNR1 and IFN-𝛼/𝛽 subtypes (Figures 5(a)–5(c)).
By contrast, IFN-𝛼 and IFN-𝛽 were correlated to each other
but not to IFNR1 in PBMCs (Figures 5(d)–5(f)). Having
observed a highly coordinated expression of type I IFN
components in GALT compared to that measured in PBMCs,
we evaluated whether there was any correlation between type
I IFN activation and the frequencies of na¨ıve or memory
Th1/Tc1 and Th17/Tc17 cell subsets. We observed that IFN-
𝛼/𝛽 mRNA levels were negatively related to the frequencies
of both IFN-𝛾-producing CD4+ T and CD8+ T na¨ıve cells
and also of IFN-𝛾-producing CD8+ memory T cell subsets
(central memory and effector memory) in GALT (Table 3).
In addition, negative correlations between the IFNR1 levels
and the frequencies of both IFN-𝛾-producing CD4+ T na¨ıve
cells and the frequencies of IFN-𝛾 CD4+ central memory
and CD8+ effector memory T cells were also recorded in
GALT. By contrast, there was no relationship between type
I IFN response and IFN-𝛾-producing CD8+ or CD4+ T cell
subsets (na¨ıve, central memory, and effector memory) in the
peripheral blood compartment (data not shown). As far as the
analysis of the relationship between IFN-𝛼, IFN-𝛽, and IFNR1
production and na¨ıve and memory Th17/Tc17 response is
concerned, there was no significant relationship between
type I IFN activation and Th17/Tc17 response measured in
either GALT or peripheral blood compartments (data not
shown). Lastly, we evaluated whether there was any corre-
lation between type I IFN expression and the frequencies
of CD4+ and CD8+ T cells expressing HLA-DR, CD38 and
coexpressing CD38 and HLA-DR.We found that the amount
of IFN-𝛼 (𝑟 = 0.82, 𝑝 = 0.023) and IFN-𝛽 (𝑟 = 0.81,
𝑝 = 0.022), but not that of IFNR1, measured in GALT, was
correlated with frequencies of CD4+ T cells expressing CD38
in peripheral blood. Furthermore, levels of IFN-𝛼 and IFN-𝛽
in peripheral blood were correlated to both the frequencies
of CD4+ T cells coexpressing CD38 and HLA-DR (IFN-𝛼:
𝑟 = 0.96, 𝑝 = 0.0001; IFN-𝛽: 𝑟 = 0.92, 𝑝 = 0.003) and
those of CD8+ effector memory T cells expressing HLA-DR
measured in GALT (IFN-𝛼: 𝑟 = 0.85, 𝑝 = 0.014; IFN-
𝛽: 𝑟 = 0.78, 𝑝 = 0.36). Conversely, no relationship was
recorded between levels of type I IFN components and the
frequencies of CD4+ and CD8+ T cells expressing HLA-DR,
CD38 and coexpressing CD38 and HLA-DRmeasured in the
same compartment (data not shown).
4. Discussion
The gut mucosa is known to be a compartment where
the interplay between HIV-1 and the host’s immune system
takes center stage. Therefore, we examined the frequency,
phenotype, and functional status of T cell subpopulations in
the GALT and peripheral blood of virologically suppressed
HIV-1-infected patients on ART therapy, focusing on the
IFN-𝛾 or IL-17+ subset of CD4+ T and CD8+ T cells.
Throughout the long antiretroviral treatment, we observed
a persistent immune activation in GALT expressed by high
levels of CD4+/HLA-DR+ and CD4+CD38+/HLA-DR+ with
higher levels of Th17 and Tc17 with respect to peripheral
blood. In this regard, it has been reported that gut Th17 cells
had a much greater capacity to produce proinflammatory
8 Mediators of Inflammation
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Figure 5: Correlation among type I interferon (IFN) components in the gut-associated lymphoid tissue (GALT) and peripheral blood
mononuclear cells (PBMCs) collected from treated HIV-1-infected patients who had achieved viral load suppression (<37 HIV-1 RNA
copies/mL) in response to ART therapy. GALT: Panel (a), 𝑟 = 0.98, 𝑝 < 0.001, [IFN-𝛼 versus IFN-𝛽]; Panel (b), 𝑟 = 0.96, 𝑝 < 0.001
[IFN-𝛼 versus IFN receptor (R1)]; Panel (c), 𝑟 = 0.96, 𝑝 < 0.001 [IFN-𝛽 versus IFNR1]. PBMCs: Panel (d), 𝑟 = 0.96, 𝑝 < 0.001 [IFN-𝛼 versus
IFN-𝛽]; Panel (e), 𝑟 = 0.32, 𝑝 = 0.48 [IFN-𝛼 versus IFN receptor (R1)]; Panel (f), 𝑟 = 0.50, 𝑝 = 0.25, [IFN-𝛽 versus IFNR1]. Spearman’s rho
coefficient was used to assess the correlation between type I IFN components in GALT and PBMCs.
cytokines than did those from the blood, but this capacity was
dramatically reduced from the earliest stages ofHIV infection
[15]. Furthermore, Nigam et al. reported that Tc17 and Th17
cells were present in all lymphoid and gastrointestinal tissues
studied with predominance in small intestine [16].
Our results also confirm that prolonged antiretroviral
treatment improves GALT immune function despite the
persistence of immune activation. In this context, we spec-
ulate on the importance of discovering new therapeutic
strategies that are able to delete immune activation. In fact,
the detection of Th17 after PMA stimulation emphasizes
that unexhausted cells are present in GALT despite the
continuous status of immune activation. Our previous study
demonstrated that eight months of ART increased intestinal
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Table 3: Analysis of the relationship between type I interferon (IFN) activation and na¨ıve and memory Th1 or Tc1 cell subsets measured in
the gut-associated lymphoid tissue (GALT) of HIV-1-infected patients.
IFN-𝛾 CD4+ na¨ıve
T cell
IFN-𝛾 CD4+
central memory T
cell
IFN-𝛾 CD4+
effector memory T
cell
IFN-𝛾 CD8+ na¨ıve
T cell
IFN-𝛾 CD8+
central memory T
cell
IFN-𝛾 CD8+
effector memory T
cell
IFN-𝛼 r = −0.92 𝑟 = −0.71 𝑟 = −0.50 r = −0.80 r = −0.80 r = −0.89
p = 0.003 𝑝 = 0.071 𝑝 = 0.25 p = 0.036 p = 0.036 p = 0.007
IFN-𝛽 r = −0.92 𝑟 = −0.71 𝑟 = −0.50 r = −0.80 r = −0.80 r = −0.89
p = 0.003 𝑝 = 0.071 𝑝 = 0.25 p = 0.036 p = 0.036 p = 0.007
IFNR1 r = −0.85 r = −0.78 𝑟 = −0.57 𝑟 = −0.75 𝑟 = −0.75 r = −0.85
p = 0.014 p = 0.036 𝑝 = 0.18 𝑝 = 0.052 𝑝 = 0.052 p = 0.014
∗Spearman’s rho coefficient was used to assess the correlation between type I IFN activation and naı¨ve and memory Th1 or Tc1 cell subsets. Significant
correlations are highlighted in bold.
CD4+ and Th17 cells and reduced levels of T cell activation
and proliferation and the magnitude of intestinal CD4+ T
cell reconstitution correlated with the reduction of plasma
LPS [17]. It would be useful to know if Th17 recovered
in GALT occurs through routes other than ART. In our
opinion, the type I IFN response plays a central role in
the pathogenesis of HIV-1 infection both by restricting
viral replication and spread and by contributing to chronic
immune activation which is currently considered the driving
force of acquired immunodeficiency syndrome [18]. This is
supported by somedegree of correlation found between levels
of type I IFN components and the activation of CD4+ and
CD8+ T cells. Thus, to gain new insights into the Th1/Tc1
andTh17/Tc17 response in long- term treated HIV-1-infected
patients, we also evaluated the expression of IFN-𝛼 and IFN-
𝛽 and IFNR1 and their relationships with T cell subsets in
GALT and peripheral blood compartments. Interestingly, a
more vigorous and coordinated IFN-𝛼/𝛽 and IFNR1 response
was observed in mucosal gut compared to that measured
in the peripheral blood of HIV-1-infected patients. These
findings could indicate an incomplete suppression type I
IFN immune activation in GALT despite the long-term
therapy, which could be linked to the persistingmucosal viral
burden. In agreement with the above observation,Macal et al.
demonstrated that long-term therapy could reduce, but not
fully suppress, HIV-RNA levels in the gut mucosa, although
substantial gut CD4+ T cell restoration was still possible
[19]. Limited information is available on the expression of
type I IFN pathways in the gastrointestinal tract of HIV-1-
infected patients. Previous studies examining gene expression
responses in GALT to acute-stage and chronic-stage HIV-
1 infection in ART-na¨ıve patients found a broad increase
in IFN-driven immune responses [20–22]. The clinical sig-
nificance of an upregulation of type I IFN components in
GALT compared to the peripheral compartment in long-term
treated HIV-1-infected patients remains unknown. However,
a significant increase in mucosal gene expression regulating
IFN immune activation and inflammation was detected in
chronically HIV-1-infected patients with high viral loads
but not in long-term nonprogressor patients, supporting the
evidence of a detrimental role for IFN-𝛼/𝛽 during HIV-1
infection [21]. Furthermore, previous studies found a corre-
lation between incomplete mucosal CD4+ T cell restoration
and increased immune activation in HIV infection despite
ART [19, 23, 24]. Here, we observed that IFN-𝛼/𝛽/mRNA
levels were negatively related to the frequencies of IFN-𝛾-
producing CD8+ T cell subsets (naı¨ve, central memory, and
effector memory) in GALT suggesting that the activation of
type I IFN response could have a negative impact on CD8+
T cell responses. A negative relationship between type I IFN
response and IFN-𝛾-producing CD4+ na¨ıve T cells was also
recorded. It is currently unknown whether these negative
correlations between type I IFN components and CD8+ T
cell subsets and Th1 naı¨ve cells can be considered positive
or negative in terms of HIV-1-associated enteropathogenesis.
However, it has been reported that viral suppression in long-
termnonprogressor patientsmay result, in part, fromefficient
maintenance of CD4+ T helper and HIV-1-specific CD8+ T
cell responses in both GALT and circulating lymphocytes
[21].
As far as the analysis of type I IFN activation andTh17/Th1
response was concerned, we did not found any relationships
between type I IFN activation and Th17/Tc17 response in
either compartment analyzed. By contrast, a negative impact
of type I IFN onTh17 differentiation inmultiple sclerosis [25]
or on the secretion of Th17-polarizing cytokines in human
dendritic cells [26] has recently been proposed. However, as
a variety of signals can block Th17 commitment including
that of IFN-𝛾, the highly upregulated type I IFN components
in GALT could negatively influence the production of IFN-
𝛾, thereby contributing indirectly to the restoration of Th17
during ART therapy. Further studies are urgently needed to
characterize the controversial role of type I IFN in HIV-1
disease and its relationship with IFN-𝛾 or IL-17A-producing
CD4+ T or CD8+ T cell subsets in the gastrointestinal tract of
HIV-1-infected patients.
All these findings would be greatly strengthened by
the evaluation of soluble markers of inflammation (LPS,
scCD14, IL-6, and D-dimers) and their correlation with
Th17, Th1, Tc17, Tc1 frequencies, and type I IFN components.
Another important analysis is the expression of ISGs and
other IFN-related genes to better characterize IFN activation
pathways in the peripheral blood and GALT compartments
of HIV-1 patients. Unfortunately, the material collected in
the present study was only enough for the current experi-
ments.
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In conclusion, our comparative investigation of the fre-
quency, phenotype, and functional status of Th1/Tc1 and
Th17/Tc17 cell populations in intestinal mucosa and periph-
eral compartments of long-term HIV-1-infected patients
provides new insights into the role of mucosal pathology in
HIV-1 disease progression. A significant increase in the gene
expression of type I IFN components was detected in GALT
compared to peripheral blood. This was negatively related
to IFN-𝛾-producing CD8+ T cell subsets and also to IFN-
𝛾-producing CD4+ na¨ıve T cells but not to the Th17/Tc17
response. A better understanding of the mucosal relationship
between the Th1/Th17 and Tc1/Tc17 axis and antiviral innate
defenses during HIV-1 infection will shed more light on the
mechanisms of HIV-1 enteropathogenesis.
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